We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder

By LabMedica International staff writers
Posted on 30 Sep 2019
Print article
Image: In a new study, researchers uncovered a gene network that is disrupted in ASD, noting that the disrupted gene network is related to fetal brain development in ASD models (Photo courtesy of University of California, San Diego).
Image: In a new study, researchers uncovered a gene network that is disrupted in ASD, noting that the disrupted gene network is related to fetal brain development in ASD models (Photo courtesy of University of California, San Diego).
An improperly functioning molecular network and related biomarkers are expected to help doctors diagnose autism spectrum disorder in young children and to predict the likely severity of symptoms that may develop.

Autism spectrum disorder (ASD) comprises a range of neurodevelopmental mental disorders including autism and Asperger syndrome. Individuals “on the spectrum” often experience difficulties with social communication and interaction, and they often display restricted, repetitive patterns of behavior, interests, or activities. Symptoms are typically recognized between one and two years of age. Long-term problems may include difficulties in performing daily tasks, creating and keeping relationships, and maintaining a job.

ASD is usually diagnosed by subjective observation of clinical symptoms, and no reliable, practical, and objective markers of prognosis currently exist. Hundreds of genes have been implicated in ASD, but the mechanisms through which they contribute to the disorder have not been well defined.

Investigators at the University of California, San Diego (USA) extended the efforts aimed at developing objective tests for detection and prognosis of ASD by analyzing blood gene expression data from 302 one- to four-year-old boys with and without the diagnosis of ASD.

Results revealed the existence of a perturbed gene network that included genes that were highly expressed during fetal brain development. Furthermore, the degree of dysregulation in this network correlated with the severity of ASD symptoms in the toddlers. The network was also found to be dysregulated in ASD cellular models.

"The study shows that through analyses of gene expression from ordinary blood samples, it is possible to study aspects of ASD's fetal molecular origins, uncover the functional impact of hundreds of ASD risk genes that have been discovered over the years, and develop clinical tests of ASD diagnosis and severity prognosis," said senior author Dr. Nathan E. Lewis, associate professor of pediatrics and bioengineering at the University of California, San Diego. "The genetics of ASD are extremely heterogeneous. Hundreds of genes have been implicated, but the underlying mechanisms remain murky. These findings identify how ASD genetics dysregulate a core network that influences brain development at fetal and in the very early years of life and, consequently, the severity of later ASD symptoms."

The ASD study was published in the September 23, 2019, online edition of the journal Nature Neuroscience.

Related Links:
University of California, San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.